ClinicalTrials.gg
RecruitingNCT06289673Updated Nov 17, 2026

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

A Phase 4 interventional study of Dexamethasone and Vincristine in Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma and Mixed Phenotype Acute Leukemia, sponsored by St. Jude Children's Research Hospital. Recruiting at 5 sites in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by St. Jude Children's Research Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.
Updated Nov 17, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
850
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 11 open to participants now, 19 under way, 6 of them phase 3. Dexamethasone · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
7th of 62
850 · median 49
Started
2024
with 1 other
Phase 4
6 of 63
1 open now
Primary completion
2034-05
later than 18 of 18 live
Registered
61st of 63
by date
Lead sponsor
11 of 63
St. Jude Children's Research Hospital

Among the 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 7th largest by planned enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 4, reaches primary completion later than 18 of the 18 other live ones, and was the 61st registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

11 of the 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment.

Primary Objectives

  • To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies.
  • To develop a central database of genomic and clinical findings.

Secondary Objectives

  • To assess event free and overall survival data of patients enrolled on this study.
Read the detailed description

Patients with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL/LLy) and mixed phenotype acute leukemia/lymphoma (MPAL) will undergo diagnostic procedures either during screening or on Day 1. They will receive 7 days of chemotherapy including 13 doses of dexamethasone, 1 dose of vincristine, and 1 dose of daunorubicin (for patients with T-ALL/LLy or MPAL only). Patients will also undergo their initial lumbar puncture with intrathecal chemotherapy on Days 4 or 5 or 6 of therapy. After the completion of 7 days of chemotherapy, patients will begin therapy on either a SJALL therapeutic trial or will receive non-protocol therapy.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma
  • Mixed Phenotype Acute Leukemia

Keywords

  • Newly Diagnosed
  • Risk Category
  • Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma
  • Mixed Phenotype Acute Leukemia (MPAL)
  • Children
  • Young Adults
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1-18.99 years
  • Diagnosis of acute leukemia / lymphoma as below:

    • Acute lymphoblastic leukemia (ALL) with at least 25% bone marrow blasts or definitive evidence of ALL in peripheral blood (in those without an available bone marrow sample).
    • Lymphoblastic lymphoma (LLy) with immunophenotypic evidence of a lymphoblastic population and \<25% bone marrow blasts and less than 1,000 circulating blasts/ microL.
    • Mixed phenotype acute leukemia (MPAL) with or without 25% bone marrow involvement (i.e. patients with either leukemia or lymphoma are eligible).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Receipt of prior cancer directed therapy with the exclusion of up to 1 dose of intrathecal chemotherapy, 1 dose of vincristine, or emergency radiotherapy due to organ compromising malignant mass. There is no exclusion for prior therapy.
  • Known to be permanently ineligible for available SJALL therapeutic studies (e.g. receipt of prohibited therapy, no appropriate SJALL therapeutic study available, enrolled on competing trial, etc.).

Note: The intention of this exclusion criterion is to enroll all newly diagnosed ALL/ LLy/ MPAL patients. If participant is screened as a potential participant for subsequent SJALL and later found to be ineligible due to information obtained during INITIALL, this will not make the participant ineligible for INITIALL.

  • Inability or unwillingness of research participant or legal guardian/representative to give written .
  • Major pre-existing abnormalities such as ataxia telangiectasia, Fanconi anemia, Charcot Marie Tooth, etc.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
850 participants (estimated)

Study arms

  • Experimental
    Newly diagnosed ALL, LLy, and MPAL patients

    All eligible patients receive the following intervention: Dexamethasone, Vincristine, Daunorubicin, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)

    Drug: Dexamethasone · Drug: Vincristine · Drug: Daunorubicin · Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) · Drug: Methotrexate · Drug: Cytarabine

Interventions

  • Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7

    Also known as: Decadron

  • Intravenously (IV) for 1 dose on Day 1 or 2

    Also known as: Vincristine Sulfate, Oncovin

  • Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)

    Also known as: Daunomycin

  • DrugIntrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)

    Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6

    Also known as: ITMHA

  • Given IT as part of Intrathecal triple therapy.

    Also known as: MTX, Trexall®

  • Given IT as part of Intrathecal triple therapy.

    Also known as: Cytosine arabinoside, Ara-C

06

What researchers measure

Primary outcomes

  1. Sufficient phenotypic and/or genomic data necessary for therapeutic protocol assignment by Day 8 (completion of INITIALL therapy).

    The proportion of patients with sufficient immunophenotypic, genomic, and clinical data to allow determination of eligibility for currently open trials at the enrolling institution.

    Time frame: 1 week from study entry

  2. Complete data within the INITIALL database

    The proportion of patients with complete data within the INITIALL protocol database as described in the protocol.

    Time frame: 3 months, 1 year, 3, 5 years from study entry

Secondary outcomes

  1. Event Free Survival (EFS)

    EFS will be reported as estimates using the Kaplan-Meier method.

    Time frame: 1, 3, 5 years from study entry

  2. Overall Survival (OS)

    OS will be reported as estimates using the Kaplan-Meier method.

    Time frame: 1, 3, 5 years from study entry

07

Study locations

5 of 5 sites recruiting
  • Rady Children's Hospital
    San Diego, California 92123, United States
    Recruiting
    • Victor Wong, MD · Contactvwong@rchsd.org · 858-966-5811
    • Victor Wong, MD · Principal investigator
  • Our Lady of the Lakes Regional Medical Center
    Baton Rouge, Louisiana 70809, United States
    Recruiting
  • Novant Health Presbyterian Hemby Children's Hospital
    Charlotte, North Carolina 28204, United States
    Recruiting
    • Jessica Bell, MD · Contactjbell@novanthealth.org · 704-384-1900
    • Jessica Bell, MD · Principal investigator
  • Saint Francis Children's Hospital
    Tulsa, Oklahoma 74136, United States
    Recruiting
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available at the time of article publication.

Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for May 2034, 113 months after the start.

Of 30 phase 4 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 123. This study's planned 113 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 4, 2024
StartActual
Dec 26, 2024
Primary completionEst.
May 2034
CompletionEst.
May 2039
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedKnown to be currentlypermanently ineligible for available SJALL therapeutic studies (e.g. receipt of prohibited therapy, no appropriate SJALL therapeutic study available, enrolled on competing trial, etc.).
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedKnown to be currentlypermanently ineligible for available SJALL therapeutic studies (e.g. receipt of prohibited therapy, no appropriate SJALL therapeutic study available, enrolled on competing trial, etc.).
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06289673
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Dec 26, 2024
Primary completion
May 2034 (estimated)
Completion
May 2039 (estimated)
Last update
Nov 17, 2026

Study contacts

Seth E. Karol, MD
Contact
referralinfo@stjude.org
888-226-4343
Seth E. Karol, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Vincristine · Daunorubicin · Methotrexate · Cytarabine

Start the discussion